Phlebology > Volume 24, Number 4 > Pp. 157-165

This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Guex, J J Articles by Taïeb, C Search for Related Content PubMed PubMed Citation Social Bookmarking                      What's this?

Original Articles

Assessment of quality of life in Mexican patients suffering from chronic venous disorder – impact of oral Ruscus aculeatus-hesperidin–methyl-chalcone–ascorbic acid treatment – ‘QUALITY Study’

J J Guex ^*, D M E Enriquez Vega , L Avril  , S Boussetta  and C Taïeb 

^* Cabinet de Phlébologie, 32 Boulevard Dubouchage, 06000 Nice, France; Calle Durango n° 33, cons 42C, Col. Roma Norte, 06700 México DF, Mexico; Pierre Fabre Médicament, Parc Industriel La Chartreuse 2, 81106 Castres; Public Health, Health Economics and Quality of Life Department Laboratoire Pierre Fabre, 45 Place Abel Gance, 92654 Boulogne, France

Correspondence: Dr L Avril MD, Pierre Fabre Médicament, Parc Industriel La Chartreuse 2, 81106 Castres, France Email: lucienne.avril{at}pierre-fabre.com

Objectives: The present study assessed the effect of Ruscus aculeatus-hesperidin-methyl-chalcone–ascorbic acid (HMC–AA) on the quality of life (QoL) of patients suffering from chronic venous disorders (CVDs).

Methods: An observational, multicentre and prospective study was performed with 917 Mexican patients suffering from CVD. Patients were treated with R. aculeatus–HMC–AA. After 12 weeks of treatment, the physicians then assessed the patients' symptoms and QoL using Short Form (SF-12) and Chronic Venous Insufficiency (CIVIQ) auto-questionnaires.

Results: Patients were mainly women (86.7%), overweight or obese (72.7%) or C2 (39.3%)–C3 (27.6%). All symptoms and ankle circumferences significantly improved over time, with increasing clinical, aetiological, anatomical and pathophysiological (CEAP) classes and body mass index (BMI) (P < 0.001).

Concerning QoL, all dimensions of the SF-12 score significantly improved over time (P < 0.001). Moreover, the CIVIQ scores significantly improved (P < 0.001) with increasing BMI (P < 0.002) and CEAP classes (P < 0.05).

Conclusion: R. aculeatus–HMC-AA significantly improved the symptoms and QoL of CVD patients.

Key Words: chronic venous disorders • venotonic drugs • quality of life • Ruscus aculeatus • Cyclo 3 Fort^® • Fabroven

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?